Coherus Oncology, Inc.

Coherus Oncology, Inc.

CHRSNYSE / NASDAQHealthcareSmall cap

$0.37-$0.02 (-4.4%)

Last close · Data as of Nov 20, 2026

Market cap
$242.9M
P/E
1.4x
EV / EBITDA
-1.1x
Revenue
$42.2M
Net margin
398.4%
ROCE
-155.5%

-66.4% over the last year

Coherus Oncology, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-63.0%
3M
-72.0%
6M
-75.5%
1Y
-66.4%
5Y
-98.0%

52-week range

Day change -$0.02 (-4.4%) from $0.39 to $0.37 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CHRS, bought on each weekday since 2021.

News & filings

What Coherus Oncology filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was -139 million US dollars in fiscal 2025, a year of net profit.

Strengths (1)

  • Revenue grew 59.8% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.

Read moreShow less

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Sector
Healthcare
Shares outstanding
121.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$242.9M
P/E
1.4x
P/B
4.0x
EV / EBITDA
-1.1x
EV / Sales
4.6x
P/S
5.8x
52-week high
$2.51
52-week low
$0.37

Profitability

Operating margin
-429.5%
Net margin
398.4%
EBITDA margin
-403.6%
ROE
275.4%
ROCE
-155.5%
ROIC
-1103.0%
ROA
65.0%
Asset turnover
0.16

Growth

Revenue
$42.2M
Revenue growth, 1Y
59.8%
Revenue CAGR, 3Y
-41.5%
Net profit growth, 1Y
489.4%
Free cash flow
-$138.5M

Solvency

Current ratio
1.46
Debt / Equity
0.66
Debt / Assets
0.16
CFO / Net profit
-0.82
Cash / Market cap
36.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$42.2M
Cost of revenue$13.8M
Gross profit$28.4M
Operating expenses$209.5M
Research and development$108.9M
Selling, general and administrative$100.6M
Operating income-$181.1M
Interest and other-$2.0M
Pretax income-$183.1M
Tax and other-$351.1M
Net income$168.0M

Revenue and net profit

Revenue grew 59.8% in FY2025; net profit is the dashed line.

Coherus Oncology, Inc. revenue and net profit by fiscal year
Coherus Oncology, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$211.0M-$291.8M
FY2023$257.2M-$237.9M
FY2024$26.4M$28.5M
FY2025$42.2M$168.0M

Cash flows

FY2025: -$138.5M from operations, -$138.5M free after investment (dashed).

Coherus Oncology, Inc. operating and free cash flow by fiscal year
Coherus Oncology, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$241.1M-$241.1M
FY2023-$174.9M-$174.9M
FY2024-$20.4M-$20.4M
FY2025-$138.5M-$138.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$42.2M+59.8%1Y
EBITDA
-$170.2M
Net profit
$168.0M+489.4%1Y
Cash from operations
-$138.5M
Free cash flow
-$138.5M
Revenue CAGR, 3Y
-41.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$42.2M-$170.2M$168.0M-$138.5M275.4%+59.8%+489.4%

Monthly returns

Month-by-month returns of CHRS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$258.3M
Liabilities$197.3M
Equity$61.0M
Paid-in capital$1.4B
Retained earnings-$1.4B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CHRS highlighted.

P/E against peers

CHRS trades at 1.4x earnings against a peer median of -4.2x.

  1. Coherus Oncology, Inc. (this company)1.4x

Not shown (no positive earnings and no EV / Sales): Nuvectis Pharma, Inc., Protara Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Coherus Oncology, Inc.CHRSthis company$242.9M1.4x4.0x275.4%-1.1x
Nuvectis Pharma, Inc.NVCT$256.5M-9.7x13.9x-143.6%—
Codexis, Inc.CDXS$254.5M-5.8x5.0x-87.0%-8.2x
Sight Sciences, Inc.SGHT$250.3M-6.5x3.9x-60.1%-6.1x
Protara Therapeutics, Inc.TARA$247.9M-4.3x1.3x-29.2%-3.1x
Treace Medical Concepts, Inc.TMCI$239.4M-4.1x2.7x-67.6%-7.0x
LifeMD, Inc.LFMD$235.5M16.4x10.2x62.0%-135.2x
Arcturus Therapeutics Holdings Inc.ARCT$228.5M-3.5x1.1x-30.7%-0.4x
Spok Holdings, Inc.SPOK$228.3M14.4x1.6x10.8%8.9x
Peer median—-4.2x3.3x-45.4%-6.1x

Year-to-date ROI

CHRS since 1 January, against earlier years.

Historical volatility

CHRS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Coherus Oncology, Inc. operating margin by fiscal year
Coherus Oncology, Inc. operating margin by fiscal year
DateOperating margin
FY2022-121.7%
FY2023-79.0%
FY2024-756.5%
FY2025-429.5%
LineFY2025
Cost of revenueCost Of Revenue$13.8M
Gross profitGross Profit$28.4M
Operating expensesOperating Expense$209.5M
Research and developmentResearch And Development$108.9M
Selling, general and administrativeSelling General And Administration$100.6M
Total expensesTotal Expenses$223.3M
Pretax incomePretax Income-$183.1M

Learn while you research

Academy chapters picked for Coherus Oncology, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 1.4 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Growth Investing60% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →